| Is a health priority based on burden of disease addressed by an intervention |
Yes |
TB is a leading cause of death and morbidity, especially among the poorest in the poorest countries |
| Is it a cost-effective intervention |
Yes |
TB diagnosis and treatment are among the most cost-effective public health interventions ever documented |
| Includes a measure of quality (sometimes referred to as “effective coverage”) |
Yes |
There are several robust quality indicators, including diagnostic quality, verified treatment results, and case fatality |
| Credible methods exist to identify the population needing the intervention, i.e., the denominator |
Partly |
This is the most challenging aspect of TB coverage monitoring since the true TB incidence is difficult to measure directly. However, in settings where UHC exists and under-reporting is minimal, TB notifications provide a good proxy of TB incidence. Population prevalence is directly measurable in the highest burden countries and the TB death rate is, in principle, measurable in all countries through improved vital registration. |
| Credible methods exist to identify the population receiving the intervention, i.e., the numerator |
Yes |
The information about number of people receiving quality-assured TB treatment is readily available in almost every country |
| Can be routinely measured: health management information systems or periodic household survey |
Yes |
There is an internationally recommended standard TB information system that is used in almost all countries |
| Equity disaggregation is possible by household wealth/income, gender, residence, and other key stratifiers |
Yes |
Disaggregation by age, sex, and geographical area is available from standard records. Additional disaggregations require research with special data collection |
| Measureable in comparable way across countries |
Yes |
TB case definition, diagnostic quality, treatment regimens, and treatment outcomes are internationally standardised |
